LONDON, Sept 12 (Reuters) - GlaxoSmithKline is tosell its portfolio of anaesthetic drugs to South Africa's AspenPharmacare for up to 280 million pounds ($372 million)as part of a drive by the British drugmaker to focus on coretherapy areas.
The two firms, which have a long history of workingtogether, said on Monday that Aspen would pay 180 million poundsfor the products Ultiva, Nimbex, Tracrium, Mivacron andAnectinein, plus up to 100 million pounds in milestone payments.
GSK, which had already sold the U.S. and Canadian rights tothe drugs, earned around 35 million pounds from the anaestheticsin the first half of 2016.
Aspen is also acquiring rights to the remaining GSKthrombosis drug portfolio, while the two companies are ending abroader collaboration in sub-Saharan Africa.
The South African group bought most of the thrombosis drugrights in 2013, but GSK had retained certain territories,including China, India and Pakistan.
($1 = 0.7532 pounds) (Reporting by Ben Hirschler; Editing by Alexander Smith)